• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Eylea (aflibercept)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Eylea (aflibercept)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor.

    Eylea is specifically indicated for the treatment of diabetic retinopathy of all stages, including in patients with diabetic macular edema (DME).

    Eylea is supplied as an intravitreal injection. The recommended dosage of Eylea in patients with diabetic retinopathy is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections.  Although Eylea may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when Eylea was dosed every 4 weeks compared to every 8 weeks.

    Clinical Results

    FDA Approval

    The FDA approval of Eylea for the treatment of diabetic retinopathy in DME was based on two year data from the Phase III VISTA-DME and VIVID-DME studies of 862 patients, which compared Eylea 2 mg monthly, Eylea 2 mg every two months (after five initial monthly injections), or macular laser photocoagulation (at baseline and then as needed).  In these studies, on the primary endpoint of mean change in Best Corrected Visual Acuity (BCVA) at one year, patients treated with Eylea monthly or every two months showed statistically significant improvements compared to the control group. Patients in both Eylea groups gained, on average, the ability to read approximately two additional lines on an eye chart compared with almost no change in the control group.

    The FDA approval of Eylea for diabetic retinopathy was based on six-month and one-year results from PANORAMA, a randomized, multi-center, controlled Phase 3 trial that enrolled 402 patients and was designed to investigate Eylea for the improvement of moderately severe to severe NPDR without diabetic macular edema (DME), compared to sham injection. There were three treatment arms – an observational sham injection group and two Eylea treatment groups. Eylea was dosed every eight weeks (following five initial monthly doses) or every 16 weeks (following three initial monthly doses and one eight-week interval). The primary endpoint was the proportion of patients who experienced a two-step or greater improvement in the diabetic retinopathy severity scale (DRSS) from baseline for the combined Eylea treatment groups at week 24, and for each Eylea treatment group separately (every eight-week group and every 16-week group) at week 52. The DRSS is a systematic grading scale to assess DR severity based on photographs of the retina.

    Side Effects

    Adverse effects associated with the use of Eylea for diabetic retinopathy in patients with diabetic macular edema may include, but are not limited to, the following:

    conjunctival hemorrhage

    eye pain

    cataract

    vitreous detachment

    vitreous floaters

    intraocular pressure increased

    Mechanism of Action

    Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor. Eylea is designed to block the growth of new blood vessels and decrease the ability of fluid to pass through  blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor (PLGF), two growth factors involved in angiogenesis.

    Additional Information

    For additional information regarding Eylea or diabetic retinopathy in patients with diabetic macular edema, please visit https://www.eylea.us/

    Approval Date: 2015-03-01
    Company Name: Regeneron Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 15Apr

      Five Telltale Signs You’re Ready for an Electronic TMF System

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    • 06May

      The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Clinical-Trial-Brainstorming

      FDA, Industry Tackle Problem of Including Older Adults in Trials

    • ClinicalTrialNetwork-360x240.png

      National Community-Based Research Network Would Improve Reach of Trials

    • Bottleneck-360x240.png

      Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Genetic Research and IBC Oversight Requirements

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing